An indirect comparison of bevacizumab plus cisplatin-gemcitabine and cisplatin plus pemetrexed treatment for patients with advanced first-line non-squamous non-small cell lung cancer in East Asia

• Main Authors: Chang J.W.-C., Thongprasert S., Wright E., Tsang K., Kim H.T., Ahn M.-J., Kim J.-H., Kang J.H., Kim S.-W., Walzer S.
• Format: Article
• Language: English
• Published: 2014
• Online Access: http://www.scopus.com/inward/record.url?eid=2-s2.0-79956069755&partnerID=40&md5=b8de67fedc80859ff01b76479f1b4973; http://cmuir.cmu.ac.th/handle/6653943832/3749
• Institution: Chiang Mai University

Aims: To compare the relative efficacy of bevacizumab plus cisplatin-gemcitabine chemotherapy (BevCG) with cisplatin plus pemetrexed (CP) in the first-line treatment of advanced or recurrent non-small cell lung cancer (NSCLC) in East Asian patients. In the absence of evidence from head-to-head trial...